Latest Artificial pancreas Stories
LONDON, June 18, 2010 /PRNewswire/ -- An article recently published in The Lancet reports that using an artificial pancreas system overnight can significantly reduce the risk of nocturnal hypoglycemia in children and adolescents with type 1 diabetes.(1) Moreover, the first clinical trial of an artificial pancreas system delivering both insulin and glucagon has shown that this system can prevent development of hypoglycemia.(2) The latest issue of the journal Diabetic Hypoglycemia...
JDRF Volunteer, Philanthropist, Former Internet Executive to Lead Top Funder of Cures and Treatments for People with Type 1 Diabetes and Its Complications NEW YORK, June 16 /PRNewswire-USNewswire/ -- The Juvenile Diabetes Research Foundation, a leader in type 1 diabetes research worldwide, announced today that Jeffrey Brewer has been named President and Chief Executive Officer.
Insulin-producing beta cells can proliferate in patients recently diagnosed with type 1 diabetes.
The growing use of insulin delivery devices such as pens and pumps may help individuals with diabetes optimize blood glucose control and minimize their risk for chronic health problems associated with diabetes.
After years of research and anticipation, insulin pills that could make it easier for millions of patients worldwide to manage diabetes are finally moving ahead in clinical trials and a step-closer to the medicine cabinet.
PHILADELPHIA, May 13 /PRNewswire/ -- By 2020, new cases of Type 1 diabetes in children younger than five are expected to double if current trends continue, according to a study published in The Lancet.
An artificial pancreas system that closely mimics the body's blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of patients.
Alpha cells in the pancreas, which do not produce insulin, can convert into insulin-producing beta cells, advancing the prospect of regenerating beta cells as a cure for type 1 diabetes.
CAMBRIDGE, Mass., March 16 /PRNewswire/ -- Tolerx, Inc., today announced the publication in Diabetologia, the journal of the European Association for the Study of Diabetes, of the four-year follow-up clinical data from new onset type 1 diabetes (T1DM) patients (age 12-39) who received a single short course of therapy with otelixizumab (ChAglyCD3).
Scientists in Cambridge have made a significant step towards developing a so-called "artificial pancreas" system for managing type 1 diabetes in children.
- a meat pie that is usually eaten at Christmas in Quebec
More Images (1 images) »